These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32226049)

  • 1. Refractory overactive bladder patients who chose sacral neuromodulation therapy after failed OnabotulinumtoxinA treatment: A systematic review and meta-analysis.
    Yang G; Xu Y; Qu G; Zhang Y
    PLoS One; 2020; 15(3):e0230355. PubMed ID: 32226049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment for refractory overactive bladder: a systematic review and meta-analysis of sacral neuromodulation and onabotulinumtoxinA.
    He Q; Li B; Zhang C; Zhang J; Luo D; Wang K
    Int Urogynecol J; 2021 Mar; 32(3):477-484. PubMed ID: 32661556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of OnabotulinumtoxinA versus sacral neuromodulation for refractory urinary urge incontinence: A systematic review and meta-analysis of randomized controlled trials.
    Niu HL; Ma YH; Zhang CJ
    Int J Surg; 2018 Dec; 60():141-148. PubMed ID: 30415088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?
    Zahner PM; Giusto LL; Goldman HB
    Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
    Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J
    Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
    Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder.
    Leong RK; de Wachter SG; Joore MA; van Kerrebroeck PE
    BJU Int; 2011 Aug; 108(4):558-64. PubMed ID: 21166750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of sequential third-line therapies in patients with refractory overactive bladder.
    Chow PM; Trump T; Goldman HB
    Int J Urol; 2024 Jul; 31(7):772-777. PubMed ID: 38693892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review.
    Rachaneni S; Latthe P
    Int Urogynecol J; 2017 Jun; 28(6):805-816. PubMed ID: 28083714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation.
    Elmer-Lyon CG; Streit JA; Takacs EB; Ten Eyck PP; Bradley CS
    Int Urogynecol J; 2020 May; 31(5):871-879. PubMed ID: 31222571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
    Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
    Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Two Treatment Modalities in Overactive Bladder: A Rapid Overview.
    Mirza AA; Alamoudi MA; Mirza AA; Alsubaie MA; Abuzenada MA
    Med Arch; 2022 Dec; 76(6):469-472. PubMed ID: 36937615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Women's perspective: intra-detrusor botox versus sacral neuromodulation for overactive bladder symptoms after unsuccessful anticholinergic treatment.
    Balchandra P; Rogerson L
    Int Urogynecol J; 2014 Aug; 25(8):1059-64. PubMed ID: 24633067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism and Priority of Botulinum Neurotoxin A versus Sacral Neuromodulation for Refractory Overactive Bladder: A Review.
    Zhang Y; Ji F; Liu E; Wen JG
    Urol Int; 2021; 105(11-12):929-934. PubMed ID: 34130295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
    Kaaki B; Gupta D
    PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacral neuromodulation in patients with refractory overactive bladder symptoms after failed Botulinum toxin therapy: Results in a large cohort of patients.
    Reekmans M; Janssen JMW; Vrijens DMJ; Smits MAC; van Koeveringe GA; Van Kerrebroeck PEVA
    Neurourol Urodyn; 2021 Jun; 40(5):1120-1125. PubMed ID: 33829519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.